This is the login page for PHARMA JAPAN WEB subscribers. PHARMA JAPAN WEB offers excerpts of some articles for free, but paid subscription is required to read full articles.

Today's Headlines RSS

BUSINESS

Ayumi Poised to In-License Several RA Biosimilars, Eyes 50 Billion Yen Sales by 2020

Ayumi Pharmaceutical, a rheumatic and orthopedic specialty pharma born last year, is set to in-license several biosimilars for rheumatoid arthritis (RA) treatments and leverage them to attain sales of 50 ... > Read full story
REGULATORY
Editor’s Pick: Five Healthcare Policy News Headlines for January (Feb.05)
BUSINESS
Takeda Expands ADC Collaboration with US Startup Mersana (Feb.05)
BUSINESS
FDA Panel Backs Effectiveness of Brintellix for Cognitive Dysfunction (Feb.05)
BUSINESS
Mitsubishi Tanabe to Establish Stand-Alone Sales Structure via New US Subsidiary (Feb.05)
BUSINESS
BMS, Pfizer to Codevelop Factor Xa Antidote in Japan (Feb.05)
> More Latest News

Photosmore

  
Chuikyo Ends Debate on FY2016 Reimbursement Policy Reform; Price-Based Penalty for Suspended Firms Not in Recommendation (Feb.04)Sumitomo Dainippon Looks to Tap New Drugs to Counter US Latuda LOE (Feb.04)NCC, PMDA Forge Comprehensive Collaboration Pact (Feb.03)
  
Kyowa Kirin to Boost Overseas Biz in Next 5 Years, Japan Market Unpredictable: President (Feb.02)Chuikyo Reps Want Price-Based Penalty Added to Supplementary Opinions for FY2016 Reform Proposal, MHLW Expresses Caution (Feb.01)Chugai Foresees Tepid Growth for Next 3 Years: New Biz Plan (Jan.29)

News Categories

REGULATORY
   Editor’s Pick: Five Healthcare Policy News Headlines for January(Feb.05)
   MHLW Won’t Rule Out Single-Patient Humanitarian Trials: Official(Feb.05)
   Council OKs Public Knowledge-Based Application for Capecitabine as Adjuvant Chemotherapy for Rectal Cancer(Feb.05)
BUSINESS
   Takeda Expands ADC Collaboration with US Startup Mersana(Feb.05)
   FDA Panel Backs Effectiveness of Brintellix for Cognitive Dysfunction(Feb.05)
   Mitsubishi Tanabe to Establish Stand-Alone Sales Structure via New US Subsidiary(Feb.05)
ORGANIZATION
   EFPIA Japan Lays Out Basic Principles on MSL Activities(Feb.04)
   Japanese Pharma Market to Shrink 30% over 10 Years with Annual Revisions: New PhRMA Japan Chief(Jan.22)
JPMA Expels Kaketsuken over GMP Violations, Cover-Up(Jan.22)
ACADEMIA
   Japan Oncology Society Calls for Proper Use of Opdivo(Jan.22)
   Experts Launch Japanese Society of Geriatric Pharmacy(Jan.07)
Shionogi Funding Research to Develop World’s First Drug for Preventing Postoperative Metastasis of Lung Cancer(Jan.05)

Commentary

It’s Time to Squarely Discuss Proposed Penalty through Drug Price Cuts

Lexicon

3 price-band (bracket) grouping rule:
3価格帯ルール

The Column

Don’t Accept the Offer

Archives

MHLW Won’t Rule Out Single-Patient Humanitarian Trials: Official(Feb.05)
Council OKs Public Knowledge-Based Application for Capecitabine as Adjuvant Chemotherapy for Rectal Cancer(Feb.05)
Chuikyo Ends Debate on FY2016 Reimbursement Policy Reform; Price-Based Penalty for Suspended Firms Not in Recommendation(Feb.04)
Takeda to Spin Off Consumer Healthcare Unit, New Firm to Go Live in April 2017(Feb.04)
Kyorin Ends Development of COPD Combo Drug, Returns Rights to AZ(Feb.04)

Most Read

1.
MHLW Panel Backs Approval of Novartis’s ...
2.
Chuikyo Reps Want Price-Based Penalty Ad...
3.
Takeda to Spin Off Consumer Healthcare U...
4.
Retooling Generic Business - 2: Moc...
5.
Retooling Generic Business - 1: Daiichi ...

News Calendar